AZ goes Down Under for cancer conjugate deal

AstraZeneca ($AZN) has signed a deal with Australian company Starpharma Holdings. Under the terms of the agreement, AstraZeneca will test Starpharma drug-dendrimer conjugate molecules as potential anti-cancer agents. The precise molecules were not disclosed, but do not include docetaxel or dendrimer conjugates of docetaxel, according to Starpharma. Press release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

A self-injection pen prefilled with Brussels-based UCB’s Cimzia (certolizumab pegol) has been made available this week in the U.K. after a positive opinion…

Everstone, a private equity firm specializing in India and Southeast Asia, has finally decided to shell out Rs 220 crore ($33 million) to obtain a 70% stake--a…